Business Wire

HELICAL-FUSION

13.5.2024 16:01:32 CEST | Business Wire | Press release

Share
Helical Fusion and National Institute for Fusion Science Establish 'HF Collaboration Research Group' and Dedicated Experimental Space for Early Commercial Fusion Reactor Deployment

Helical Fusion has entered a partnership agreement with the National Institute for Fusion Science (NIFS) in March 2024. NIFS has established the "HF Collaboration Research Group" with activities starting in April, special experimental research space has been dedicated onsite at NIFS, which already houses the world's largest superconductor and fusion experimental facility, for Helical Fusion.
With its support from NIFS, Helical Fusion will accelerate the realization of the world's first commercial fusion reactor.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507957768/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Co-Founder, CEO of Helical Fusion Takaya Taguchi (left) and Chief of Industry-Academia-Government Coordination Section of NIFS Ryo Yasuhara (right), shake hands at NIFS in Toki-City, Gifu, Japan. (Photo: Business Wire)

[Background]
Against the backdrop of a projected global population increase of ~1.7 billion by 2050* and the corresponding surge in worldwide electricity demand, conventional power generation methods alone are expected to struggle to meet these needs. Fusion power offers a clean and safe alternative, utilizing inexhaustible fuel supplies, such as seawater, and thus holds the promise as a technology capable of fundamentally addressing these global challenges. With Japan's energy self-sufficiency rate at a low of 13.3% and fossil fuel dependency still exceeding 80%**, research and development efforts have been underway to secure future baseload power sources.

NIFS, boasting one of the world's largest fusion experimental facilities, the Large Helical Device (LHD) in Gifu prefecture, Japan, has been at the forefront of research into helical-type fusion reactors since its establishment by the government in 1989, yielding remarkable results on a global scale. Building on NIFS's expertise, Helical Fusion was founded in 2021, leveraging the speed and agility typical of startups to lead the development of the world's first commercial steady fusion reactor.

While individual collaborative research efforts have been ongoing with NIFS, the firm establishment of the "HF Collaboration Research Group" going forward, as well as a dedicated experimental space, marks a significant step toward strengthening cooperation, aimed towards the early social implementation of fusion energy.
Reference: for the press release from the National Institute for Fusion Science, click here)

[Comment from Mr. Takaya TAGUCHI (Co-founder, CEO of Helical Fusion)]
Helical Fusion is a startup born from the wealth of cutting-edge research achievements and expertise accumulated by NIFS over more than 30 years. We have conducted numerous joint research projects with NIFS in areas such as high-temperature superconducting magnets and liquid metal blankets. Given the growing global expectations of the helical-stellarator fusion approach, to operate as a steady-state commercialized reactor, we have further strengthened our collaboration to accelerate development by establishing this department, as well as setting up dedicated experimental research space. This will not only accelerate joint research but also advance progress in our proprietary tech development, particularly in the field of high-temperature superconducting magnets. We express our feelings of appreciation to the NIFS team for their cooperation and strive to meet everyone's expectations by furthering our efforts in research and development, so as to lead development with global competition towards an operation ready, steady-state fusion reactor. Furthermore, we aim to contribute to the creation of industries where Japan's proud technologies, from basic research to high-end manufacturing, can be leveraged.

[Comment from Mr. Ryo Yasuhara (Chief of Industry-Academia-Government Coordination Section, NIFS)]
The National Institute for Fusion Science has established a collaborative research department with Helical Fusion, called the "HF Collaboration Research Group", in order to conduct research and development for the practical implementation of helical-type fusion reactors. This joint research group will mainly contribute the specialized knowledge and resources of Helical Fusion and NIFS to conduct research activities aimed at realizing helical-type fusion reactor. NIFS aims to contribute to the advancement of fusion science and the establishment of a broad foundation for science and technology through research activities at the highest global standards. We hope that the achievements obtained in this research group will be a step towards realizing sustainable energy.

*“World Energy Outlook 2023” International Energy Agency (https://www.iea.org/reports/world-energy-outlook-2023)
**”The white paper on energy usage 2022”, Agency for Natural Resources and Energy (https://www.enecho.meti.go.jp/about/whitepaper/2023/pdf/)

[About Us]
Helical Fusion is a Japanese start-up company aiming at the social implementation of fusion energy with a magnetic confinement fusion reactor.
Various fusion methods have been developed in the world over the past 60 years as a next generation energy source.
In Japan, the helical fusion method, which uses a superconducting helical coil with a double-helical structure similar to DNA to stably confine high-temperature plasma, has been developed and nurtured to a great extent. We are aiming to develop the world's first steady-state fusion reactor by incorporating more advanced technologies into the helical-stellarator type fusion reactor.
Additionally, Helical Fusion's proprietary development efforts, including high-temperature superconducting magnet vital for realizing commercial reactors, have received Japanese SBIR grant funding, further accelerating progress towards commercialization.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240507957768/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye